Extracellular Vesicle Markers of Platelet Activation: Clinical Relevance and Emerging Insights

Abstract

Extracellular vesicles (EVs) have emerged as crucial biomarkers and mediators of intercellular communication in various physiological and pathological states. Platelet-derived extracellular vesicles (PEVs), in particular, are increasingly recognized for their role in reflecting and modulating platelet activation, a central event in thrombosis and inflammation. This review synthesizes contemporary evidence on the clinical significance of PEV markers, their mechanistic underpinnings, and the implications for diagnosis, prognosis, and therapeutic strategies in cardiovascular and thromboinflammatory diseases.

Introduction

Platelets are not only essential effectors of hemostasis but also dynamic participants in immune modulation and vascular homeostasis. Upon activation, platelets release a heterogeneous population of extracellular vesicles, including microvesicles and exosomes, which carry surface markers and bioactive cargo reflective of their parental cells. The identification and characterization of these vesicles offer a unique window into real-time platelet activation and related pathologies, particularly in the context of cardiovascular and systemic inflammatory disorders. This review aims to provide an in-depth analysis of the markers associated with platelet-derived EVs, their mechanistic roles, and their clinical applications based on current literature.

Epidemiology / Disease Burden

Thrombotic diseases, including myocardial infarction, stroke, and venous thromboembolism, remain leading causes of morbidity and mortality worldwide. Platelet activation is a central contributor to the pathogenesis of these conditions. Epidemiological studies have demonstrated elevated levels of PEVs in patients with acute coronary syndromes, ischemic stroke, and other thromboinflammatory disorders. The global burden of disease related to aberrant platelet activation and the increasing prevalence of associated risk factors underscore the need for reliable biomarkers, such as PEVs, in early detection and risk stratification.

Pathophysiology

Platelet-derived extracellular vesicles are shed from the plasma membrane upon activation by agonists such as thrombin, collagen, or ADP. The biogenesis of PEVs involves cytoskeletal rearrangement, calcium influx, and phospholipid redistribution, particularly the externalization of phosphatidylserine. These vesicles encapsulate a spectrum of proteins, nucleic acids, and lipids, and express platelet-specific surface markers such as CD41 (glycoprotein IIb), CD61 (glycoprotein IIIa), CD62P (P-selectin), and annexin V. Mechanistically, PEVs propagate procoagulant activity, enhance leukocyte recruitment, and modulate endothelial cell function, thus amplifying thromboinflammatory responses.

Risk Factors

Multiple clinical and environmental factors influence the generation and profile of platelet-derived EVs. Classical cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidemia, and smoking are associated with increased PEV release. Chronic inflammatory states, autoimmune diseases, malignancies, and infections also contribute to heightened platelet activation and EV production. Pharmacological agents, including antiplatelet and anticoagulant therapies, have been shown to modulate PEV levels, suggesting a dynamic interplay between clinical interventions and EV biology.

Clinical Features

While the direct clinical manifestations of elevated PEVs are not overt, their presence and levels correlate strongly with disease severity and adverse outcomes in various conditions. In acute coronary syndromes, higher circulating PEVs are associated with increased risk of recurrent ischemic events and mortality. Similarly, in systemic inflammatory diseases, PEVs serve as surrogate markers for endothelial dysfunction and microvascular injury. Their utility extends to monitoring disease progression and response to therapy in both acute and chronic settings.

Diagnosis

The detection and quantification of PEVs rely on advanced analytical techniques, primarily flow cytometry, nanoparticle tracking analysis, and electron microscopy. Key markers used for the identification of platelet-derived EVs include CD41, CD61, and CD62P, often in combination with annexin V to assess procoagulant potential. Standardization of pre-analytical and analytical protocols remains a challenge, but ongoing efforts by expert panels and consensus guidelines are improving reproducibility and comparability across studies. Emerging technologies, such as single-vesicle profiling and high-sensitivity assays, are poised to enhance diagnostic accuracy and clinical utility.

Treatment & Management

While PEVs are not direct therapeutic targets, their modulation reflects the efficacy of existing antiplatelet and anticoagulant therapies. Agents such as aspirin, P2Y12 inhibitors, and glycoprotein IIb/IIIa antagonists have demonstrated reductions in PEV levels in both clinical trials and mechanistic studies. Novel therapeutic approaches aimed at inhibiting EV release or neutralizing their pathogenic effects are in early stages of development, with the potential to attenuate thromboinflammatory processes more specifically and safely.

Recent Advances / Emerging Therapies

Recent research has focused on elucidating the molecular cargo of PEVs, including microRNAs, cytokines, and growth factors, which may serve as both biomarkers and therapeutic targets. The use of high-throughput proteomics and transcriptomics has expanded our understanding of the functional heterogeneity of PEVs in different clinical contexts. Experimental therapies targeting the biogenesis and release of EVs such as inhibitors of ARF6 or calpain pathways are being explored in preclinical models. Additionally, engineered EVs with tailored cargo offer novel avenues for drug delivery and immune modulation in cardiovascular and inflammatory diseases.

Guideline Recommendations

Current clinical guidelines, particularly from cardiovascular and hematological societies, acknowledge the prognostic value of platelet activation markers but do not yet incorporate PEV quantification into routine practice. However, expert consensus statements suggest that PEV analysis may be beneficial in high-risk populations, for monitoring therapy, and as a research tool in clinical trials. Continued standardization and validation of EV assays are essential for their eventual integration into evidence-based guidelines.

Conclusion

Platelet-derived extracellular vesicles represent a promising frontier in the identification and monitoring of platelet activation in thromboinflammatory diseases. Their characterization provides valuable insights into disease mechanisms, risk assessment, and therapeutic efficacy. Advances in detection technologies and a deeper understanding of their functional roles are paving the way for clinical translation. Ongoing research and guideline development will determine the optimal application of PEV markers in personalized medicine and patient care.